BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
Rhea-AI Summary
BlossomHill Therapeutics (Nasdaq: BLSM), a clinical-stage biopharmaceutical company focused on small molecule cancer therapies, priced its upsized initial public offering of 9,375,000 common shares at $16.00 per share, for expected gross proceeds of $150.0 million before costs and any underwriter option exercise.
BlossomHill granted underwriters a 30-day option for up to 1,406,250 additional shares at the public price, less discounts and commissions. All shares are offered by the company. Trading on the Nasdaq Global Select Market is expected to begin on August 7, 2026 under the ticker BLSM, with closing expected on August 10, 2026, subject to customary conditions.
BlossomHill’s pipeline includes lead clinical candidates BH-30643 for EGFR-mutant NSCLC and BH-30236 for R/R AML or HR-MDS, plus preclinical KRAS program BH-501284.
Positive
- $150.0 million gross IPO proceeds expected before costs
- Upsized offering of 9,375,000 shares at $16.00 per share
- Additional underwriter option for up to 1,406,250 shares
- Listing on Nasdaq Global Select Market under ticker BLSM
- Multiple oncology programs including clinical assets BH-30643 and BH-30236
Negative
- IPO issues 9,375,000 new shares, increasing share count and dilution
- Underwriters’ 30-day option could add up to 1,406,250 further shares
News Explained
If completed, the IPO would dilute existing ownership; the stated $150.0 million is gross before offering costs.
The priced IPO would increase BlossomHill Therapeutics’ share count because all offered shares are company-issued, reducing existing holders’ percentage ownership if the expected
The stated
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, today announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of
The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol “BLSM.” The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.
J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical programs include BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with an initial development focus in the C797S resistance population after 3rd generation EGFR TKI treatment, and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS) and BH-501284, our preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors. BlossomHill Therapeutics is headquartered in San Diego, California.
Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com
Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com
